Home › Calculator › TKPHF Dividend Calculator 2026
TKPHF Dividend DRIP Calculator 2026
3.84% YieldHealthcareTakeda Pharmaceutical Company Limited · OTC
Price: $34.00 · Annual div: $1.30/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When TKPHF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your TKPHF snowball 📈
$10,000 in TKPHF → $341.8K in 10 years · $91.89/month
About Takeda Pharmaceutical Company Limited (TKPHF) — Dividend Analysis 2026
Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market. This includes the research, development, production, commercialization, and external licensing of its pharmaceutical products across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and other parts of Asia. The company concentrates its therapeutic endeavors on key medical areas such as digestive health (gastroenterology), rare disorders, treatments derived from blood plasma, cancer care (oncology), and neurological conditions. Its extensive portfolio features numerous well-known brands, including Entyvio, Takhzyro, Velcade, Livtencity, and Dexilant, among others. Takeda actively cultivates a wide-ranging network of strategic partnerships and collaborations. This includes out-licensing agreements, for example with Neurocrine Biosciences, Inc.; in-licensing deals and research collaborations with organizations like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and joint research efforts with companies such as Crescendo Biologics and Skyhawk Therapeutics. Furthermore, Takeda maintains strategic alliances with entities like Evotec SE and KSQ Therapeutics, underscoring its commitment to external innovation.
Compare TKPHF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full TKPHF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TKPHF position with:
🌍 TKPHF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold TKPHF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.84% | 1.04% | $384 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.26% | 0.46% | $326 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.07% | 0.27% | $307 / yr |
| 🇬🇧 UK ISA | 0% | 3.84% | 1.04% | $384 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.50% | 0.70% | $350 / yr |
| 🇨🇦 TFSA | 0% | 3.84% | 1.04% | $384 / yr |
| 🇨🇦 CA Taxable | 25% | 2.88% | 0.08% | $288 / yr |
| 🇦🇺 Super (pension) | 15% | 3.26% | 0.46% | $326 / yr |
| 🇦🇺 AU Taxable | 30% | 2.69% | -0.11% | $269 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.83% | 0.03% | $283 / yr |
| 🇫🇷 FR Taxable | 30% | 2.69% | -0.11% | $269 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 TKPHF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $1.30/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 TKPHF Dividend Payment Schedule
TKPHF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 TKPHF vs Healthcare Benchmarks
How TKPHF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TKPHF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ TKPHF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where TKPHF earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TKPHF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Takeda Pharmaceutical Company Limited (TKPHF) is currently trading at $34.00, 7% below its 52-week high. The current dividend yield is 3.84% based on an annual payout of $1.30 per share.
TKPHF (Takeda Pharmaceutical Company Limited) — 3.84% Dividend Yield Analysis
Takeda Pharmaceutical Company Limited (TKPHF) is a healthcare stock currently trading at $34.00 with a dividend yield of 3.84%. The company pays an annual dividend of $1.30 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, TKPHF has grown its dividend at a compound annual rate of 9.8%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.